Literature DB >> 11753078

Mucosa-associated lymphoid tissue lymphoma.

Andrew Charles Wotherspoon1, Ahmet Dogan, Ming-Qing Du.   

Abstract

Since the first description of mucosa-associated lymphoid tissue (MALT) lymphoma in 1983 rapid advances have been made in the understanding of the pathogenesis and underlying molecular events associated with the development of this tumor. Lymphoma arises at extranodal sites in which a pre-existing inflammatory response has provoked the acquisition of organized lymphoid tissue. Specific molecular events have been associated with the development of MALT lymphoma including t(11;18) and alterations in Bcl-10 protein expression, and these appear to be interlinked. In gastric MALT lymphoma Helicobacter pylori is the most common stimulus for the acquisition of lymphoid tissue. Eradication of this organism has been shown to result in regression of the tumor in many cases, but there are a few that will not respond to this approach. Predicting those cases unlikely to respond to H pylori eradication alone has been investigated in a number of ways. An underlying t(11;18) within the tumor cells appears to predict for a lack of response. Clinical measurement of the depth of infiltration of the wall by gastric MALT lymphoma as measured by endoscopic ultrasound has been less clear. More superficial tumors are more likely to respond, but regression has been reported even in cases with local lymph node involvement. For superficial lymphomas at other sites alternatives to radiotherapy, chemotherapy, or surgery have been sought. Local injections of interferon (IF) alpha have been successful in treating conjunctival lymphoma, and this approach may be of use for other superficial lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11753078     DOI: 10.1097/00062752-200201000-00009

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  10 in total

1.  BALToma masquerading as pulmonary tuberculosis.

Authors:  Rahul Magazine; Hameed Aboobackar Shahul; Vidya Monappa; Bharti Chogtu
Journal:  BMJ Case Rep       Date:  2014-11-14

2.  Extragastric MALT lymphoma.

Authors:  A C Wotherspoon
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

3.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

4.  Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience.

Authors:  B Mihaljević; R Nedeljkov-Jancić; V Vujicić; D Antić; S Janković; N Colović
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

5.  A case of an enlarged medial rectus muscle.

Authors:  David Rossman; Rene Michel; Francois Codere
Journal:  Int Ophthalmol       Date:  2008-06-19       Impact factor: 2.031

Review 6.  Gastric neoplasia.

Authors:  Pelayo Correa
Journal:  Curr Gastroenterol Rep       Date:  2002-12

7.  Helicobacter pylori (H. pylori) molecular signature in conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.

Authors:  C-C Chan; J A Smith; D F Shen; R Ursea; P LeHoang; H E Grossniklaus
Journal:  Histol Histopathol       Date:  2004-10       Impact factor: 2.303

8.  Gastric biopsies: the gap between evidence-based medicine and daily practice in the management of gastric Helicobacter pylori infection.

Authors:  Hala El-Zimaity; Stefano Serra; Eva Szentgyorgyi; Rajkumar Vajpeyi; Amir Samani
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

Review 9.  Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Chung-Wu Lin; Jyh-Ming Liou; Ming-Shiang Wu; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

10.  MALT Lymphomas.

Authors:  Sami N Malek; Amy J Hatfield; Ian W Flinn
Journal:  Curr Treat Options Oncol       Date:  2003-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.